Effectiveness and safety of follitropin delta in routine clinical practice in the Nordics and Switzerland (the NORSOS study): a prospective non-interventional study.

ABSTRACT:

Background

Follitropin delta is the first approved human recombinant follicle-stimulating hormone treatment administered through an algorithmic individualized dosing regimen based on body weight and anti-Müllerian hormone (AMH) levels. This study assesses the effectiveness and safety profile of follitropin delta in women naïve to in vitro fertilization or intracytoplasmic sperm injection undergoing their first assisted reproductive technology cycle in a general clinical setting.

Study design

This prospective observational study was conducted from August 2022 to March 2024 across 14 fertility clinics in Denmark, Norway, Sweden, and Switzerland. Consenting women with infertility (≥18 years old) receiving their first assisted reproductive technology cycle and first folli

SUBMITTER: Pinborg A 

PROVIDER: S-EPMC12446022 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature